Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 B, 2010, Pages 1645-1656

  Steinmetz, Martin ^a   Brouwers, Caroline ^a   Nickenig, Georg ^a   Wassmann, Sven ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Angiotensin receptor blockers; Endothelial progenitor cells; PPAR ; Statins; Telmisartan

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; LECTIN; LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; TELMISARTAN;

ADULT; ANIMAL; APOPTOSIS; ARTICLE; C57BL MOUSE; CELL COUNT; CELL MOTION; CLONOGENIC ASSAY; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIUM CELL; HUMAN; METABOLISM; MOUSE; SPLEEN; STEM CELL;

ADULT; ANIMALS; APOPTOSIS; BENZIMIDAZOLES; BENZOATES; CELL COUNT; CELL MOVEMENT; COLONY-FORMING UNITS ASSAY; DRUG SYNERGISM; ENDOTHELIAL CELLS; HUMANS; LECTINS; LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; REACTIVE OXYGEN SPECIES; SIMVASTATIN; SPLEEN; STEM CELLS;

MUS;

EID: 77955152492     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00829.x     Document Type: Article

References (50)

1. Giannotti G, Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis. Herz. 2007, 32:568-72.
2. Werner N, Nickenig G. Endothelial progenitor cells in health and atherosclerotic disease. Ann Med. 2007, 39:82-90.
3. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008, 28:1584-95.
4. Sieveking DP, Buckle A, Celermajer DS. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol. 2008, 51:660-8.
5. Asahara T, Murohara T, Sullivan A. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997, 275:964-7.
6. Lin Y, Weisdorf DJ, Solovey A. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000, 105:71-7.
7. Wassmann S, Werner N, Czech T. Improvement of endothelial function by systemic transfusion of vascular progenitor cells. Circ Res 2006, 99:e74-83.
8. Werner N, Junk S, Laufs U. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003, 93:e17-24.
9. Werner N, Wassmann S, Ahlers P. Endothelial progenitor cells correlate with endothelial function in patients with coronary artery disease. Basic Res Cardiol. 2007, 102:565-71.
10. Heeschen C, Lehmann R, Honold J. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation. 2004, 109:1615-22.
11. Hill JM, Zalos G, Halcox JP. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003, 348:593-600.
12. Laufs U, Werner N, Link A. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation. 2004, 109:220-6.
13. Vasa M, Fichtlscherer S, Aicher A. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001, 89:E1-7.
14. Werner N, Kosiol S, Schiegl T. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005, 353:999-1007.
15. Min TQ, Zhu CJ, Xiang WX. Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2004, 18:203-9.
16. Dimmeler S, Aicher A, Vasa M. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001, 108:391-7.
17. Werner N, Priller J, Laufs U. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol. 2002, 22:1567-72.
18. Werner C, Kamani CH, Gensch C. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes. 2007, 56:2609-15.
19. Li X, Xu B. HMG-CoA reductase inhibitor regulates endothelial progenitor function through the phosphatidylinositol 3'-kinase/akt signal transduction pathway. Appl Biochem Biotechnol. 2008, 157:545-53.
20. Walcher D, Marx N. Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action. Diab Vasc Dis Res. 2004, 1:76-81.
21. Gensch C, Clever YP, Werner C. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis. 2007, 192:67-74.
22. Caballero AE, Saouaf R, Lim SC. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism. 2003, 52:173-80.
23. Schupp M, Janke J, Clasen R. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004, 109:2054-7.
24. Benson SC, Pershadsingh HA, Ho CI. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004, 43:993-1002.
25. Walenta K, Friedrich EB, Sehnert F. In vitro differentiation characteristics of cultured human mononuclear cells-implications for endothelial progenitor cell biology. Biochem Biophys Res Commun. 2005, 333:476-82.
26. Petoumenos V, Nickenig G, Werner N. High density lipoprotein exerts vasculoprotection via endothelial progenitor cells. J Cell Mol Med. 2009, 13:4623-35.
27. Kobayashi K, Imanishi T, Akasaka T. Endothelial progenitor cell differentiation and senescence in an angiotensin II-infusion rat model. Hypertens Res. 2006, 29:449-55.
28. Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens. 2005, 23:97-104.
29. Benndorf RA, Gehling UM, Appel D. Mobilization of putative high-proliferative-potential endothelial colony-forming cells during antihypertensive treatment in patients with essential hypertension. Stem Cells Dev. 2007, 16:329-38.
30. Yao EH, Fukuda N, Matsumoto T. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res. 2007, 30:1119-28.
31. Yu Y, Fukuda N, Yao EH. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am J Hypertens. 2008, 21:72-7.
32. Zhao Y, Foryst-Ludwig A, Bruemmer D. Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation. J Neurochem. 2005, 94:1395-401.
33. Imayama I, Ichiki T, Inanaga K. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006, 72:184-90.
34. Assmus B, Urbich C, Aicher A. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res. 2003, 92:1049-55.
35. Henrich D, Seebach C, Wilhelm K. High dosage of simvastatin reduces TNF-alpha-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1beta in vitro. J Surg Res. 2007, 142:13-9.
36. Llevadot J, Murasawa S, Kureishi Y. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001, 108:399-405.
37. Spyridopoulos I, Haendeler J, Urbich C. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation. 2004, 110:3136-42.
38. Urbich C, Knau A, Fichtlscherer S. FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells. FASEB J. 2005, 19:974-6.
39. Lee S, Kim W, Moon SO. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant. 2006, 21:2096-105.
40. Miura M, Satoh S, Inoue K. Telmisartan pharmacokinetics in Japanese renal transplant recipients. Clin Chim Acta. 2008, 399:83-7.
41. Dormandy JA, Charbonnel B, Eckland DJ. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005, 366:1279-89.
42. Ikejima H, Imanishi T, Tsujioka H. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J Hypertens. 2008, 26:964-72.
43. Li AC, Brown KK, Silvestre MJ. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000, 106:523-31.
44. Nissen SE, Nicholls SJ, Sipahi I. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006, 295:1556-65.
45. Nissen SE, Nicholls SJ, Wolski K. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008, 299:1561-73.
46. Wassmann S, Czech T, van Eickels M. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation. 2004, 110:3062-7.
47. Wassmann S, Hilgers S, Laufs U. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002, 22:1208-12.
48. Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction-modulation by statins. Endothelium. 2003, 10:23-33.
49. Yusuf S, Teo K, Anderson C. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008, 372:1174-83.
50. Ridker PM, Danielson E, Fonseca FA. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359:2195-207.